Is third-generation IVF really suitable for everyone? 90% of people get it wrong – read this before making your decision!

Published: 2026-06-28 |Views: 7009

In recent years, with the continuous development of assisted reproductive technology, IVF has helped more and more families welcome their own babies. Among the many technologies, third‑generation IVF in Thailand, with its advanced embryo screening techniques, high‑level laboratories, and mature clinical experience, has become a popular choice for many families. However, during daily consultations, Global New Life has found that many people still hold misconceptions about third‑generation IVF.

Some believe: “Third generation must be more advanced than first and second, and it gives the highest success rate.” Others think: “Since we are already doing IVF, going straight to third generation can’t be wrong.” And quite a few families assume: “Third‑generation IVF is a panacea – as long as we do it, we will definitely get pregnant.”

In fact, none of these views are entirely correct. Third‑generation IVF is not an “upgraded version” and is not a must‑choose option for everyone. Its greatest value lies in helping specific groups reduce the risk of genetic diseases and screen out embryos with chromosomal abnormalities, thereby improving the utilization of high‑quality embryos. However, it also has specific indications and limitations.

So, what exactly is third‑generation IVF? Who is suitable for it? Can it really increase success rates? Should all families planning overseas fertility treatment or cross‑border childbearing choose the third generation? Today, Global New Life will clarify these questions once and for all.

I. What exactly is third‑generation IVF? It is not “a newer, better version”

Many families new to assisted reproduction mistakenly believe that first generation < second generation < third generation. Actually, this is a very common misunderstanding. The so‑called first, second, and third generations are not technological upgrades, but rather different treatment options for different causes of infertility.

In simple terms:

First‑generation IVF (IVF)

It mainly uses in vitro fertilization, allowing eggs and sperm to naturally combine in the laboratory to form embryos. This technique is more suitable for female tubal factors, ovulation disorders, and similar conditions.

Second‑generation IVF (ICSI)

In the second‑generation technique, under a microscope, a laboratory specialist injects a single sperm directly into the oocyte to achieve fertilization. It is mainly applicable to male factor infertility such as low sperm count, poor motility, or fertilization difficulties.

Therefore, the main difference between first and second generation is simply the method of fertilization.

Third‑generation IVF (PGT)

What truly draws wide attention to third‑generation IVF is the addition of a key technology – preimplantation genetic testing (PGT) of embryos. It does not change the fertilization method but adds a genetic analysis of embryos before transfer, helping doctors select embryos that better meet the criteria for transfer.

Thus, it can be understood as: First and second generations are responsible for successfully combining sperm and egg; the third generation adds a genetic screening step after embryo formation.

For this reason, many families preparing for third‑generation IVF in Thailand now prioritize learning about PGT technology, hoping to reduce the risk of chromosomal abnormalities before transfer as much as possible.

II. What exactly is PGT? It actually includes three different types of testing

What many people call “third‑generation IVF” is actually PGT. But in reality, PGT is not a single test but a collective term for three different testing approaches. Different populations need to choose different types.

① PGT‑M – for monogenic genetic diseases

PGT‑M is mainly applicable to couples where one or both partners are known carriers of a specific monogenic genetic disease.

Examples include:

Thalassemia
Hemophilia
Spinal muscular atrophy (SMA)
Cystic fibrosis and some other monogenic disorders

Through testing, embryos without the pathogenic gene can be selected for transfer, reducing the risk of passing on genetic diseases to the next generation at its source. For families with a clear family history of genetic disorders, this technology has great significance.

② PGT‑SR – for chromosomal structural abnormalities

Some couples show no obvious abnormalities in their own checkups but repeatedly experience:

Implantation failure
Recurrent miscarriage
Biochemical pregnancy
Fetal arrest

Upon further examination, it is found that one partner carries a chromosomal structural abnormality such as balanced translocation or Robertsonian translocation. Although such carriers usually show no symptoms themselves, the embryos they produce may have chromosomal abnormalities, affecting pregnancy outcomes.

The role of PGT‑SR is to help select embryos with normal chromosomal structure, improving the chance of pregnancy.

③ PGT‑A – currently the most widely used

If there is one test that is most common, it is PGT‑A. It mainly detects whether the embryo has the correct number of chromosomes.

As women age, egg quality declines, and the probability of chromosomal abnormalities increases. Especially after age 35, this risk begins to rise significantly; after 38 or 40, the abnormal rate increases further.

Chromosomal numerical abnormalities are often a major cause of:

Transfer failure
Biochemical pregnancy
Fetal arrest
Early miscarriage
Some fetal chromosomal disorders

Therefore, for women of advanced maternal age, those with repeated implantation failure, recurrent miscarriage, etc., PGT‑A can help doctors select chromosomally normal embryos and improve subsequent transfer efficiency. Of course, it should be emphasized that PGT‑A mainly targets chromosomal numerical abnormalities; it cannot cover all diseases, nor is it necessary for every family.

III. Why are more and more people choosing third‑generation IVF? The real advantage is more than just “screening”

When many people learn about third‑generation IVF in Thailand, their first reaction is: “If we do the third generation, will we definitely get pregnant?” In fact, the real advantage of third‑generation IVF is not “guaranteeing success,” but rather providing doctors with more valuable information through genetic testing before transfer, so they can select embryos that are more suitable for transfer. In other words, its value lies in improving the efficiency of embryo utilization, not in creating a healthy embryo that did not exist.

Therefore, the first concept to understand is: PGT cannot improve embryo quality; it can only screen embryo quality. If the number of embryos formed is low, or overall embryo quality is poor, even with third‑generation technology, one cannot “create” more healthy embryos.

Therefore, no matter which IVF option is chosen, high‑quality eggs, high‑quality sperm, and good laboratory culture conditions remain the essential foundation for treatment outcomes.

IV. Why do chromosomal abnormalities affect pregnancy?

To understand the importance of PGT, we first need to know: What are chromosomes? Normal human cells contain 46 chromosomes – 23 from the father and 23 from the mother. When sperm and egg combine, these 46 chromosomes recombine to form a new life. Under normal circumstances, each pair of chromosomes should be complete and equal in number.

However, if errors occur during egg maturation, sperm formation, or cell division after fertilization, there may be: an extra chromosome, a missing chromosome, or abnormal segregation of part of a chromosome. This is medically termed chromosomal aneuploidy. And this is a major cause of many pregnancy failures.

What effects can chromosomal abnormalities have?

Many families have experienced situations like: embryos with good grading still fail to implant; pregnancy is confirmed but hCG levels decline, leading to biochemical pregnancy; everything seems normal initially but then fetal arrest occurs; or early miscarriage happens after a positive test.

Often, these issues are not coincidental but may be closely related to embryonic chromosomal abnormalities. In addition, a very small number of embryos with chromosomal abnormalities may still develop and be born, but the baby may have severe chromosomal disorders, such as: Down syndrome (trisomy 21); Edwards syndrome (trisomy 18); Patau syndrome (trisomy 13).

Thus, the importance of chromosomal testing lies not only in improving transfer efficiency but also in reducing the risk of some chromosomal disorders.

V. What practical value does PGT‑A offer?

For those who meet the indications, PGT‑A provides several advantages.

1. Improving the efficiency of selecting high‑quality embryos

In the past, without genetic testing, doctors mainly selected embryos based on morphology. Although a higher grade usually indicates better development, a good appearance does not guarantee normal chromosomes. PGT‑A can further test whether the embryo has the correct chromosome number, allowing doctors to prioritize embryos that are more suitable for transfer among multiple blastocysts. For families with a larger number of embryos, this screening method can help optimize the transfer sequence and improve treatment efficiency.

2. Reducing the time cost of repeated transfers

Many families planning overseas fertility treatment or choosing third‑generation IVF in Thailand hope to minimize the number of treatment cycles. For those who have experienced multiple failed transfers, each wait means enormous time, physical, and psychological pressure. With PGT screening, ineffective attempts due to transferring chromosomally abnormal embryos can be reduced, shortening the time needed to achieve a successful pregnancy to some extent. It should be noted that specific outcomes are still influenced by age, embryo quality, endometrial environment, and many other factors; there is no fixed result applicable to everyone.

3. Reducing the risk of some early miscarriages

Clinical studies have found that chromosomal abnormalities are a major cause of early spontaneous miscarriage. For those with a history of recurrent miscarriage, biochemical pregnancy, or fetal arrest, choosing PGT‑A after professional evaluation can help reduce the risk of another miscarriage due to embryonic chromosomal abnormalities. Of course, this does not mean that miscarriage will not occur after PGT, because many factors beyond chromosomes affect pregnancy.

For example: endometrial receptivity; uterine malformations; endometritis; endocrine imbalances; immune factors; thrombophilia; sperm DNA fragmentation rate in the male partner; lifestyle and age – all may affect the final pregnancy outcome. Therefore, third‑generation IVF is just one important part of the overall treatment, not the sole determinant.

4. Helping to reduce the risk of some chromosomal disorders

PGT‑A can identify common chromosomal numerical abnormalities, thus reducing the risk of fetal diseases caused by such abnormalities. However, it must be emphasized: reducing risk ≠ completely eliminating risk.

PGT mainly targets known detection ranges. For de novo mutations, some monogenic diseases, problems caused by environmental factors, and new changes during pregnancy, PGT cannot cover everything. Therefore, even after third‑generation IVF, routine prenatal examinations and follow‑ups are still necessary as advised by the doctor.

Global New Life Reminder: The more advanced the technology, the more it requires a professional team.

Many families focus solely on the “third‑generation technology” itself but overlook another key factor – laboratory standards and medical team experience. In fact, PGT involves multiple high‑precision steps including blastocyst culture, embryo biopsy, genetic testing, cryopreservation, etc. Each step requires a mature laboratory system and strict quality control.

Therefore, whether in China or choosing third‑generation IVF in Thailand, the overall strength of the medical institution, laboratory standards, and team experience all have a significant impact on the entire treatment process. As a professional organization focusing on overseas fertility treatment, cross‑border childbearing, and overseas patient accompaniment, Global New Life always helps each family evaluate scientifically and plan rationally based on their own circumstances, rather than blindly pursuing a particular technology.

VI. Is third‑generation IVF a panacea? These limitations must be understood in advance

As third‑generation IVF in Thailand gains more attention, many families preparing for IVF develop a misconception: “Since third generation can screen embryos, does that mean I won’t fail if I do it?”

The answer is no. Although PGT can help select embryos that meet the testing criteria, it cannot solve all the factors affecting pregnancy, nor can it guarantee 100% success. Therefore, before deciding whether to choose third‑generation IVF, it is equally important to correctly understand both its advantages and limitations.

Limitation 1: PGT cannot screen for all diseases

Many people think: “If we do third generation, the baby will definitely have no problems.” In fact, this is one of the biggest misunderstandings about PGT. Currently, PGT mainly targets:

Chromosomal numerical abnormalities (PGT‑A)
Chromosomal structural abnormalities (PGT‑SR)
Known monogenic genetic diseases (PGT‑M)

That is to say, it can only analyze genetic issues that can be clearly detected.

If it involves: de novo mutations, polygenic diseases, developmental abnormalities caused by environmental factors, or new changes occurring during pregnancy – these cannot be entirely prevented by PGT.

Therefore, even after completing third‑generation IVF, routine prenatal checks such as: NT scan, non‑invasive prenatal testing (NIPT), systematic ultrasound, and when necessary, amniocentesis, must still be performed on time. PGT cannot replace prenatal testing; the two complement each other.

Limitation 2: PGT accuracy is not 100%

Many families ask: “Can the test results be wrong?” In current international clinical practice, PGT has relatively high accuracy, but no medical test can achieve 100% perfection. There are two main reasons.

First: The tested cells are not the same cells that will develop into the fetus

During embryo biopsy, doctors usually extract cells from the trophectoderm of the blastocyst – which will mainly form the placenta. The cells that will actually become the fetus are the inner cell mass. Therefore, the test result represents the overall chromosomal situation but may not be absolutely identical.

Second: Embryos may have mosaicism

Some embryos may contain both normal and abnormal cells during development. This is called a mosaic embryo. With deeper research in recent years, some low‑level mosaic embryos, after professional evaluation, may still have the potential to develop into a healthy baby. Therefore, the current international approach to mosaic embryos is increasingly individualized, rather than simply deeming them “untransplantable.” This is why the experience of specialist doctors is so important.

Limitation 3: A normal screen does not guarantee a successful pregnancy

Many families believe: “Normal embryo = guaranteed pregnancy.” In reality, implantation is influenced by a complex set of factors.

Uterine factors

Including: thin endometrium, endometritis, uterine fibroids, adenomyosis, intrauterine adhesions, uterine malformations – all can affect embryo implantation.

Endocrine factors

For example: thyroid dysfunction, elevated prolactin, luteal phase deficiency, polycystic ovary syndrome – all can affect the entire pregnancy process.

Immunological and coagulation factors

In recent years, more studies have found that in some patients with repeated implantation failure, the problem may not be the embryo but rather: immune abnormalities, antiphospholipid syndrome, or thrombophilia – all of which also require comprehensive evaluation by specialists.

Male factors

Many families tend to overlook male factors. In fact, even if the routine semen analysis is normal, if the DNA fragmentation index is high, sperm chromosomes are abnormal, or sperm maturation is inadequate, embryo development can still be affected. Therefore, there is now growing emphasis on both partners being examined and evaluated together.

VII. Who is more suitable for third‑generation IVF?

Although third‑generation IVF has clear advantages, not every family needs PGT. Based on current clinical application, the following groups are more likely to benefit from discussing with their doctor whether third‑generation IVF is appropriate.

① Those with recurrent spontaneous miscarriage

If there have been two or more consecutive miscarriages, especially when clearly related to embryonic chromosomal abnormalities, doctors may recommend further evaluation for PGT suitability.

② Repeated embryo transfer failures

If multiple IVF cycles have been performed with reasonably good embryo quality but pregnancy has never been achieved, a comprehensive analysis of chromosomal abnormalities, uterine environment, and other factors is needed.

③ Advanced maternal age

As age increases, the probability of chromosomal abnormalities in eggs rises. Especially: after 35, it starts to increase; after 38, the risk increases further; over 40, individualized assessment becomes more critical. However, it must be noted that advanced age does not necessarily mean third generation is a must; it also depends on ovarian reserve, number of eggs retrieved, and embryo quality.

④ Known carriers of genetic diseases or chromosomal abnormalities

If one or both partners have: monogenic genetic disorders, balanced translocations, Robertsonian translocations, or other chromosomal structural abnormalities, PGT‑M or PGT‑SR can help reduce genetic risks, thus usually having clear medical indications.

⑤ Others with clear medical indications

Beyond these, whether to choose third‑generation IVF should be comprehensively evaluated by a specialist based on age, medical history, previous pregnancies, genetic test results, etc., rather than following trends blindly.

Global New Life Reminder: The best plan is the one that fits you

In recent years, more families are choosing to go abroad for assisted reproductive services, and third‑generation IVF in Thailand, with its mature technology and rich clinical experience, has become a popular choice. However, it must be emphasized that whether domestically or overseas, third‑generation IVF is not “the more advanced, the better,” but “the more suitable, the better.”

As a professional organization focusing on overseas fertility treatment, cross‑border childbearing, and overseas patient accompaniment, Global New Life always adheres to scientific evaluation as the foundation, helping each family develop personalized plans based on their own circumstances, rather than simply recommending one technology over another. Only a plan that truly suits you can help improve treatment efficiency and reduce unnecessary time and financial costs.

VIII. Another key factor before opting for third‑generation IVF – do not overlook it

When consulting, many families focus on: “Should I do the third generation?” Actually, the first question should be: “Do I have enough good‑quality embryos to be screened?” Because PGT is only a “screening” tool, not a “creation” tool.

If the number of eggs retrieved is small or the embryo culture yield is limited, after screening, the number of embryos that meet transfer criteria may be correspondingly reduced. Especially for older women, ovarian reserve declines with age, affecting both egg quantity and quality. This is why some older women, after stimulation and retrieval, may obtain a certain number of eggs but end up with few usable blastocysts; after PGT, the number available for transfer may decrease further.

Therefore, before entering an IVF cycle, actively improving overall health and egg/sperm quality is often more important than simply focusing on “which generation of IVF” to choose.

IX. Choosing a professional institution also determines the entire treatment experience

Apart from the technology itself, another important factor often overlooked is the medical institution and laboratory standards. For third‑generation IVF in Thailand, the entire process includes not only stimulation, egg retrieval, and embryo culture, but also blastocyst culture, embryo biopsy, genetic testing, cryopreservation, and embryo thawing. Each step requires a mature laboratory system and strict quality control.

For example: Does the lab have stable blastocyst culture techniques? Is embryo biopsy performed properly? Is the genetic testing process robust? Does the laboratory environment meet international standards? Does the medical team have extensive experience? All these factors affect the stability of the entire treatment process.

Therefore, for families planning to go abroad, choosing a well‑experienced, well‑managed, and well‑serviced medical institution is often more important than pursuing a particular technology.

X. Understand third‑generation IVF scientifically to make the choice that suits you best

In recent years, with the continuous advancement of assisted reproductive technology, more families have realized their fertility dreams through overseas treatment. Among them, third‑generation IVF in Thailand, with its mature laboratory technology, standardized medical processes, and rich clinical experience, has become a focus of attention for many.

But it must be emphasized again: third‑generation IVF is not a “master key,” nor is it mandatory for everyone. Its greatest value lies in helping those with medical indications undergo genetic screening before embryo transfer, reducing the risk of some chromosomal abnormalities or genetic diseases, and improving the utilization of high‑quality embryos.

At the same time, it has specific indications, limitations, and a certain embryo attrition rate. Therefore, whether choosing first, second, or third generation, the decision should be based on professional evaluation, not blindly following trends. The plan that truly suits you is the better plan.

Warm reminder from Global New Life

For every family, IVF is not just a medical technology, but a journey that requires patience, trust, and perseverance. When planning overseas fertility treatment or cross‑border childbearing, instead of blindly pursuing a certain technology, it is better to first thoroughly understand your own physical condition and then develop a reasonable plan based on professional advice.

As a professional organization focused on overseas assisted reproduction, Global New Life always puts client needs at the core, providing one‑stop services from initial consultation, hospital matching, travel planning, translation and communication, to overseas patient accompaniment for families in need, helping each family navigate the cross‑border medical process with greater ease.

We believe that every family’s situation is unique, and no single plan suits everyone. Scientific evaluation, rational choice, and standardized treatment are the essential foundations for improving overall efficiency. May every family striving to welcome new life avoid unnecessary detours and soon embrace their own moment of happiness.

Summary

Third‑generation IVF is not “the more advanced the better,” but rather a precision assisted reproductive technology for specific populations. It can help eligible families screen for some chromosomal and genetic abnormalities in embryos, improving the utilization of high‑quality embryos, but it cannot replace other key factors such as embryo quality, uterine environment, endocrine status, and pregnancy management.

For families planning to choose third‑generation IVF in Thailand, it is recommended to make decisions based on professional evaluation, taking into account age, medical history, genetic risks, and reproductive plans. At the same time, choosing an institution with mature laboratories, a professional team, and a comprehensive service system is also a crucial part of the entire treatment process that should not be overlooked.